Disinfecting Cleaner helps prevent acquired infections.
Share:
Press Release Summary:
T36® DC is a safe infection control product that simultaneously cleans and disinfects in janitorial and sanitation applications. Able to kill bacteria responsible for nosocomial (hospital-acquired) infections, product is also suited for use in schools, cruise ships, airlines, and child-care facilities.
Original Press Release:
ALDA Pharmaceuticals Introduces T36® Disinfecting Cleaner
Vancouver, BC, May 17 2005 - ALDA Pharmaceuticals Corp. (APH:TSX-V) (the "Company") is pleased to announce it has successfully completed independent laboratory testing of its new T36® Disinfectant Cleaner ("T36® DC"). T36® DC simultaneously cleans and disinfects. It is the Company's second product in a line of T36® based infection control products. The Company will introduce T36® DC to janitorial and sanitation distributors who are seeking a safe, effective cleaner with proven disinfectant capability. T36® DC has been tested for its cleaning properties and its ability to kill bacteria responsible for nosocomial (hospital-acquired) infections. Results have shown that T36® DC has the potential to provide low cost and effective cleaning and disinfection solutions to major new markets such as schools, hospitals, cruise ships, airlines and child-care facilities. Independent studies project demand for disinfectant and antimicrobial chemicals in the United States alone, will grow nearly 6 percent annually to $735 million in 2007.
President & CEO, Dr Terrance Owen, states "We have been working diligently on the development of new products and this is the next of many to come. We feel that the T36® Disinfectant Cleaner will help the company fulfill the potential we saw when we were first introduced to T36® technology."
About ALDA Pharmaceuticals Corp.
ALDA Pharmaceuticals Corp. has developed a family of wide spectrum, non-toxic, non-corrosive, biodegradable infection control products based on its patent pending T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.
Terrance G. Owen, Ph.D., MBA
President & CEO
ALDA Pharmaceuticals Corp.
www.aldacorp.com
Distribution & Sales Contact
Aaron Genereaux
(604) 521- 8300
aaron@aldacorp.com
Broker & Analyst Contact
Scott Young
(778) 371-9100 ext 1220
scott_young@aldacorp.com
Shareholder & Investor Contact
Dan Byrne
(888) 998-8886
dan_byrne@aldacorp.com
